Clinical trials
Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma clinical trials
Below are recruiting relapsed or refractory b-cell non-hodgkin lymphoma clinical trials, each written for real people, not researchers. We’re tracking 1,758 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07586618RecruitingPhase 1
New Drug 4A10 for Hard-to-Treat Lymphoblastic Leukemia or Lymphoma
This is an early-stage study testing a new experimental drug (4A10) in patients whose acute lymphoblastic leukemia or lymphoblastic lymphoma has returned or stopped responding to standard treatments. Researchers want to learn if the drug is safe and how it works in the body.
Aurora, ColoradoAges 18 years+ - NCT07025564RecruitingPhase 1
MiRisten for relapsed or refractory AML
This phase 1 trial tests a new treatment called MiRisten for people with acute myeloid leukemia (AML) that has come back or not responded to previous treatments. The goal is to see if the drug is safe and effective.
Duarte, CaliforniaAges 18 years+ - NCT07075185RecruitingPhase 1
Gene therapy study for hard-to-treat multiple myeloma
This study tests a new gene therapy for people with multiple myeloma that has come back or stopped responding to at least 3 prior treatments. The therapy is designed to help your immune system fight the cancer cells more effectively.
Duarte, CaliforniaAges 18 years+ - NCT06940297RecruitingPhase 2
Dasatinib and quercetin with CAR-T therapy for relapsed or refractory multiple myeloma
This trial tests whether adding two drugs, dasatinib and quercetin, to CAR-T therapy can help people with multiple myeloma that has come back or not responded to past treatments. It aims to make the CAR-T cells work better and reduce side effects.
Rochester, MinnesotaAges 18 years+ - NCT06060873Recruiting
Using a blood test to find active germ cell tumors
This trial tests whether a blood test called miRNA-371 can detect active germ cell tumors in patients who have had surgery or are being watched. It may help guide treatment decisions without needing extra biopsies or scans.
Birmingham, AlabamaAges 18 years+ - NCT06495723RecruitingPhase 1/Phase 2
Antibody therapy for relapsed T-cell lymphoma
This trial tests a new experimental antibody therapy for people with certain types of peripheral T-cell lymphoma that have not responded to or have come back after prior treatment. The study aims to see if the treatment is safe and effective.
CaenAges 18 years+ - NCT07218146RecruitingPhase 3
Study of ZL-1310 vs Standard Care for Relapsed Small Cell Lung Cancer
This trial tests a new drug, ZL-1310, against standard treatments for people with small cell lung cancer that has returned after initial therapy. The goal is to see if ZL-1310 works better than other options.
La Jolla, CaliforniaAges 18 years+ - NCT06622005RecruitingPhase 1
Combination treatment for multiple myeloma that has returned
This trial tests a new drug (SX-682) added to a standard three-drug combination (carfilzomib, daratumumab, and dexamethasone) for people whose multiple myeloma has come back or stopped responding to previous treatment. The goal is to see if adding this drug helps control the cancer better.
Buffalo, New YorkAges 18 years+ - NCT02688894Recruiting
Molecular testing for relapsed small cell lung cancer
This study uses tumor tissue to look for molecular (biologic) changes after your small cell lung cancer comes back. It may help doctors choose the most appropriate next treatment based on what the cancer’s biology shows.
IncheonAges 20 years+ - NCT06695013RecruitingPhase 2
Maintenance therapy after CAR-T for low-risk B-cell lymphoma
This study tests whether adding a type of maintenance therapy after CAR-T cell treatment helps people with low-risk B-cell lymphoma that has returned or not responded to standard treatments. It compares the standard CAR-T approach to one with extra immune-supporting treatment.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06006273RecruitingPhase 1
Testing a new drug combo for children with returning solid tumors
This trial tests a new combination of three chemotherapy drugs (eribulin, irinotecan, and temozolomide) for children and young adults whose solid tumors have come back or not responded to standard treatment. The goal is to see if this combination is safe and effective.
Houston, TexasAges 1–25 - NCT04629833RecruitingPhase 3
Mesenchymal cells vs standard care for steroid-resistant graft-versus-host disease
This trial studies a type of immune-support cell therapy (mesenchymal stromal cells) compared with the best available standard treatment for acute graft-versus-host disease (aGvHD) that does not respond to steroids. It may help by calming an overactive immune reaction after a stem cell transplant.
AmiensAges 12 years+ - NCT07237230Recruiting
Gamma-delta T cells to prevent leukemia relapse after transplant
This trial tests if a special type of immune cell called gamma-delta T cells can help prevent acute myeloid leukemia from coming back after a stem cell transplant. It is for people with high-risk features who have recently had a transplant.
Wuhan, HubeiAges 18–65 - NCT05625594RecruitingPhase 1
Test brain-directed CAR T cells for CNS lymphoma
This Phase 1 study tests a new type of immune therapy (CAR T cells) placed directly into the fluid around the brain to treat central nervous system (CNS) lymphoma. It mainly looks at safety and how well the treatment can control the lymphoma when other CNS treatments have not worked.
Duarte, CaliforniaAges 18 years+ - NCT02677064Recruiting
Study on barriers to stem cell transplant for acute leukemia
This study looks at what makes it hard for people with acute leukemia or related blood cancers to get a stem cell transplant. It aims to find ways to help more people get this treatment.
Hartford, ConnecticutAges 18–80 - NCT06203210RecruitingPhase 3
Study of a new drug for relapsed small cell lung cancer
This study tests a new drug, ifinatamab deruxtecan, against the doctor's choice of standard treatments for people with extensive-stage small cell lung cancer that has returned after initial platinum-based chemotherapy. The goal is to see if the new drug works better and if it might be a new option for you.
Springdale, ArkansasAges 18 years+ - NCT06796504Recruiting
Nerve stimulation for relapsing-remitting multiple sclerosis
This trial tests a device that stimulates a nerve in the neck, which may help repair the protective coating around nerves in the brain and spinal cord. It is for people with relapsing-remitting MS who are stable on their current medication and have some vision problems due to MS.
Irvine, CaliforniaAges 22–60 - NCT06084936RecruitingPhase 3
Glofitamab alone vs other treatments for mantle cell lymphoma
This trial tests a new drug called glofitamab to see if it works better than other standard treatments for people with mantle cell lymphoma that has come back or not responded to previous therapy. It is for patients who have already tried a BTK inhibitor and at least one other treatment.
Berkeley, CaliforniaAges 18 years+ - NCT07587125RecruitingPhase 1
CAR-T Cell Therapy for Progressive Multiple Sclerosis
This trial tests a new cell therapy called S103 for people with MS that isn't responding well to standard treatments. The therapy involves modifying immune cells in the lab and putting them back into your body to help control the disease.
Xi'an, ShaanxiAges 18–75 - NCT06232044RecruitingPhase 1/Phase 2
Testing a new drug combo for returning multiple myeloma
This trial tests a combination of two approved drugs (lenalidomide and dexamethasone) plus an experimental drug (iberdomide) for people with multiple myeloma that has returned or stopped responding to treatment. It aims to see if this new combination can help control the disease.
Ames, IowaAges 18 years+ - NCT06931626RecruitingPhase 1
Study of NMS-03305293 for relapsed small cell lung cancer
This trial tests a new drug, NMS-03305293, in adults with small cell lung cancer that has come back after earlier treatments. The goal is to see if it can help shrink or slow the cancer.
Peoria, IllinoisAges 18 years+ - NCT06131840RecruitingPhase 1
Study of SGN-CEACAM5C for advanced solid tumors
This trial tests a new drug called SGN-CEACAM5C in people with advanced solid tumors that have not responded to other treatments. The drug targets a protein on cancer cells to try to stop them from growing.
Phoenix, ArizonaAges 18 years+ - NCT03214562RecruitingPhase 1/Phase 2
Venetoclax plus chemotherapy for acute leukemia
This trial studies how well venetoclax combined with chemotherapy treats newly diagnosed or returning (relapsed) or hard-to-treat (refractory) acute myeloid leukemia (AML). It’s mainly for people who can’t use standard AML therapy well, or whose disease came back.
Houston, TexasAges 18 years+ - NCT03629171RecruitingPhase 2
Venetoclax plus chemo to treat certain AML types
This trial tests a combination of venetoclax with liposome chemotherapy (daunorubicin and cytarabine) for adults with acute myeloid leukemia (AML) that is back after treatment or not responding, and for some newly diagnosed cases. It aims to shrink leukemia and help more people achieve remission.
Houston, TexasAges 18 years+
Hear when a new Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for relapsed or refractory b-cell non-hodgkin lymphoma?
- Yes. Clin2 currently lists 1,758 recruiting relapsed or refractory b-cell non-hodgkin lymphoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a relapsed or refractory b-cell non-hodgkin lymphoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a relapsed or refractory b-cell non-hodgkin lymphoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.